Enliven Therapeutics Inc.
ELVN | NASDAQ
$48.54
-$0.33 (-0.68%)
Sep 22, 2026, 11:01 AM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 14K | 46K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 24K | 25K | 25K |
Gross Profit | n/a | -14K | -46K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -24K | -25K | -25K |
Operating Income | -37.21M | -27.82M | -34.29M | -25.1M | -28.58M | -31.69M | -26.9M | -27.07M | -24.6M | -25.99M | -22.73M | -24.25M | -20.13M | -16.42M | -10.16M | -10.93M | -9.02M | -8.68M | -8.4M | -13.66M | -13.17M | -10.28M |
Interest Income | 4.73M | 4.2M | 4.62M | 4.95M | 3.25M | 3.2M | 3.72M | 3.84M | 4.09M | 3.25M | 3.37M | 3.49M | 3.41M | 1.69M | 613K | 380K | 127K | 9K | 3K | 30K | 48K | 83K |
Pretax Income | -32.49M | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.72M | -22.74M | -19.37M | -20.77M | -16.72M | -14.72M | -9.55M | -10.55M | -8.89M | -8.67M | -8.39M | -13.65M | -13.16M | -10.26M |
Net Income | -32.49M | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M | -20.77M | -16.72M | -14.72M | -9.55M | -10.55M | -8.89M | -8.67M | -8.39M | -13.65M | -13.16M | -10.26M |
Selling & General & Admin | 8.21M | 7.14M | 13.04M | 6.87M | 7.09M | 6.8M | 6.17M | 5.81M | 5.78M | 6.02M | 4.82M | 3.34M | 3.65M | 4.54M | 1.97M | 3.11M | 1.08M | 1.62M | 1.53M | 3.24M | 3.07M | 3.14M |
Research & Development | 29M | 20.69M | 21.25M | 18.23M | 21.49M | 24.9M | 20.72M | 21.26M | 18.83M | 19.97M | 17.91M | 19.61M | 15.18M | 11.88M | 8.2M | 7.83M | 7.94M | 7.06M | 6.86M | 10.4M | 10.07M | 7.12M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.3M | 1.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 37.21M | 27.82M | 34.24M | 25.1M | 28.58M | 31.69M | 26.9M | 27.07M | 24.6M | 25.99M | 22.73M | 24.25M | 20.13M | 16.42M | 10.16M | 10.93M | 9.02M | 8.68M | 8.4M | 13.64M | 13.14M | 10.26M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -24K | -25K | -25K |
Cost & Expenses | 37.21M | 27.82M | 34.29M | 25.1M | 28.58M | 31.69M | 26.9M | 27.07M | 24.6M | 25.99M | 22.73M | 24.25M | 20.13M | 16.42M | 10.16M | 10.93M | 9.02M | 8.68M | 8.4M | 13.66M | 13.17M | 10.28M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 232K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 66.17M | 62.8M | 56.66M | 62.09M | 52.11M | 50.05M | 49.86M | 48.27M | 48.08M | 42.05M | 41.13M | 41.03M | 40.96M | 18.52M | 6.57M | 6.57M | 6.57M | 6.57M | 6.57M | 6.23M | 4.43M | 4.39M |
Shares Outstanding (Diluted) | 66.17M | 62.8M | 56.66M | 62.09M | 52.11M | 50.05M | 49.86M | 48.27M | 48.08M | 42.05M | 41.13M | 41.03M | 40.96M | 18.52M | 6.57M | 6.57M | 6.57M | 6.57M | 6.57M | 6.23M | 4.43M | 4.39M |
EPS (Basic) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 | -0.80 | 4.90 | -0.70 | -1.74 | -2.23 | -2.18 | -2.19 | -2.97 | -2.33 |
EPS (Diluted) | -0.49 | -0.38 | -0.45 | -0.32 | -0.49 | -0.57 | -0.46 | -0.48 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 | -0.80 | 4.90 | -0.70 | -1.74 | -2.23 | -2.18 | -2.19 | -2.97 | -2.33 |
EBITDA | -32.49M | -23.61M | -29.62M | -20.09M | -25.25M | -28.47M | -23.1M | -23.08M | -19.64M | -22.66M | -19.29M | -20.69M | -16.65M | -14.66M | -9.49M | -10.49M | -8.84M | -8.63M | -8.36M | -13.62M | -13.14M | -10.23M |
EBIT | -32.49M | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.72M | -22.74M | -19.37M | -20.77M | -16.72M | -14.72M | -9.55M | -10.55M | -8.89M | -8.67M | -8.39M | -13.65M | -13.16M | -10.26M |
Depreciation & Amortization | n/a | 14K | 46K | 62K | 81K | 74K | 80K | 80K | 78K | 79K | 78K | 78K | 74K | 67K | 64K | 60K | 52K | 39K | 33K | 24K | 25K | 25K |
Add to Watchlist
Select watchlists to add or remove ELVN